Litcius/Paper detail

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients

Di Wang, C. Zeng, Bin Xu, Jian Xu, Junshuai Wang, Lijun Jiang, Qianheng Wang, Chunrui Li, Nengchao Wang, Liang Huang, Y.-C. Zhang, Yi Xiao, Jianfeng Zhou

2020Blood Cancer Journal59 citationsDOIOpen Access PDF

Topics & Concepts

CD30Chimeric antigen receptorLymphomaMedicineRefractory (planetary science)AntigenOncologyImmunologyCancer researchInternal medicineImmunotherapyBiologyImmune systemAstrobiologyCAR-T cell therapy research
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients | Litcius